While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Last week marked the FDA's deadline for compounders to stop making the obesity drug tirzepatide (Zepbound), leaving some ...

The 62-year-old comic and actress, who suffers from diabetes, made the admission while updating fans on her recent move to Ireland - in protest at the Donald Trump administration - and the significant ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Amy Schumer’s experience with Mounjaro has been vastly different from when she tried an alternative weight-loss medication ...

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

Antiobesity medications tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.